Table 5. Factors associated with IPT completion among PLHIV in Kenya, 2015–2018.

Variables	uOR	(95% CI)	p-value	aOR	95% CI	p-value
Where IPT was prescribed (n = 3,891)
CCC	Ref
In-Patient	1.03	(0.14–7.68)	0.9	0.79	(0.1–5.96)	0.8
MCH/PMTCT	0.55	(0.33–0.92)	0.02	0.66	(0.39–1.12)	0.1
Out-Patient	1.4	(0.65–3.02)	0.4	1	(0.46–2.21)	0.9
TB Clinic	0.47	(0.06–3.68)	0.5	0.24	(0.03–1.98)	0.2
Facility level (n = 3,891)
level 2	Ref
level 3	0.95	(0.62–1.46)	0.8	0.98	(0.63–1.51)	0.9
level 4	0.48	(0.33–0.71)	0	0.5	(0.33–0.74)	0.001
level 5	0.56	(0.26–1.23)	0.1	0.39	(0.17–0.90)	0.03
Type of Facility(n = 3,891)
GoK	Ref
FBO	1.71	(1.06–2.75)	0.03	1.65	(1.02–2.68)	0.04
Private	0.59	(0.42–0.83)	0.002	0.61	(0.43–0.87)	0.006
IPT duration Prescription (n = 3,891)
< month	Ref
Monthly	1.83	(0.96–3.5)	0.07	2.13	(1.10–4.13)	0.03
Every 2 m	3.58	(1.71–7.48)	0.001	4.22	(1.99–8.95)	<0.01
Every 4 m	2.48	(1.18–5.19)	0.02	3.01	(1.39–6.52)	0.005
Above 4 m	7.12	(1.55–32.83)	0.01	7.65	(1.64–35.7)	0.01
Routine screen(n = 3,891)
Yes	Ref
No	0.65	(0.38–1.10)	0.1
Sex(n = 3,891)
Female	Ref
Male	0.81	(0.59–1.10)	0.2
Age-group (n = 3,891)
0–9	Ref
10–14.	1.33	(0.47–3.76)	0.6
15–19	0.91	(0.32–2.59)	0.9
20–25	1.53	(0.61–3.87)	0.4
25+	1.45	(0.75–2.82)	0.3
Viral load before IPT (n = 1,596)
Suppressed	Ref
Not Suppressed	1.14	(0.48–2.71)	0.8
Viral load After IPT (n = 3348)
Suppressed	Ref
Not Suppressed	0.61	(0.35–1.08)	0.09
ART initiation (n = 3891)
Before	Ref
After	0.59	(0.31–1.15)	0.1

uOR–unadjusted Odds Ratio; aOR–adjusted Odds Ratio; CI—Confidence interval; CCC–comprehensive care clinics; MCH/PMTCT–maternal and child health/ prevention of mother to child transmission; TB–tuberculosis; GoK–the government of Kenya; FBO–faith-based organization; IPT–isoniazid preventive therapy; ART–antiretroviral therapy

In bold–statistically significant at P<0.05